Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Heart Evaluation of Acute ischemic stroke with Reperfusion Therapy (HEART) is a single-center observational registry evaluating the heart of patients hospitalized for acute ischemic stroke with reperfusion therapy.
This registry aims to establish quantified risk stratification and prognostic models, as well as suggest effective diagnostic and therapeutic strategies.
There is growing evidence pointing to close interactions between acute ischemic stroke (AIS) and heart diseases. Heart diseases may lead to AIS (heart-to-brain interactions), with many cardiac conditions have been proposed as potential sources of cerebral embolism, and studies have also shown that AIS can induce cardiac injury (brain-to-heart interactions), namely Stroke-Heart Syndrome. In addition, due to the commonly shared risk factors, AIS patients had a significantly higher frequency of coexisting prior known or unknown coronary heart disease (brain-and-heart interactions). These heart problems not only add complexity to the etiological diagnosis but also account for a great proportionate mortality in AIS patients with reperfusion therapy, which is the most effective treatment method for AIS. The interconnected and coexisting properties of AIS and heart diseases requires a comprehensive scheme to evaluate, prevent, and treat patients.
Heart Evaluation of Acute ischemic stroke with Reperfusion Therapy (HEART) is a single-center observational registry evaluating the heart of patients hospitalized for acute ischemic stroke with reperfusion therapy.
This registry aims to establish quantified risk stratification and prognostic models, as well as suggest effective diagnostic and therapeutic strategies.
The clinical, laboratory and imaging information will be collected at the baseline. During an estimated 3-year follow-up, the diagnostic or monitoring procedures, treatment, functional status and new vascular events will be recorded by web-based patients' self-reports, investigators' regular telephone visits.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Heart Evaluation of Acute ischemic stroke with Reperfusion Therapy | Acute ischemic stroke within 24 h after onset of stroke-related symptoms. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| observational only- no intervention | Other | observational only- no intervention |
|
| Measure | Description | Time Frame |
|---|---|---|
| Rate of Major Adverse Cardiovascular Events | cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of Major Adverse Cardiovascular Events | ardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina | 90 days |
| Functional Outcome |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Acute ischemic stroke patients within 24 h after onset of stroke-related symptoms.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jianqiang Ni, MD, PhD | Contact | +8617640052675 | buildingdoc@163.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The first affiliated hospital of soochow university | Recruiting | Suzhou | Jiangsu | 215000 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000083242 | Ischemic Stroke |
| ID | Term |
|---|---|
| D020521 | Stroke |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
anticoagulant peripheral blood, serum
Percentage of patients with modified Rankin Scale (mRS) scores (minimum 0 and maximum 5) 3 to 5, who are considered to be disabled. |
| 90 days |
| Rate of Ischemic Stroke | fatal and nonfatal ischemic stroke. | 1 year |
| Rate of Acute Coronary Syndrome | fatal and nonfatal myocardial infarction and unstable angina | 1 year |
| Rate of Cardiovascular Mortality | any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death | 1 year |
| Time to First Major Adverse Cardiovascular Event | from the date of enrollment until the date of first documented cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction or unstable angina, whichever comes first, assessed up to 3 years | 3 years |
| Time to First Ischemic Stroke | from the date of enrollment until the date of first documented ischemic stroke, assessed up to 3 years | 3 years |
| Rate of Major Adverse Cardiovascular Events | cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina | 3 years |
| Rate of Ischemic Stroke | fatal and nonfatal ischemic stroke | 3 years |
| Rate of Acute Coronary Syndrome | fatal and nonfatal myocardial infarction and unstable angina | 3 years |
| Rate of Cardiovascular Mortality | any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death | 3 years |
| D009422 |
| Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |